Country Overview
Key Facts
Number of Employees: Approximately 500
Main Brands:
Marlboro, Eve, Bond Street, Multifilter, Philip Morris, L&M
Welcome to Philip Morris Hungary. We were established in 1992 after Philip Morris International acquired the Eger Tobacco Factory. Today, we are the second largest tobacco company in the country.
Philip Morris Hungary distributes its products through a direct sales distribution system, providing nationwide coverage. Overall, about 500 employees work for Philip Morris Hungary, predominantly in the sales organization.
Our brand portfolio includes international brands like Marlboro and L&M, as well as regional and local brands such as Eve and Multifilter.
Philip Morris Hungary has an active charitable contributions program, supporting initiatives in the communities where our employees live and work. Our contributions activities focus on programs such as helping the homeless and also provide support for other initiatives intended to benefit the local community.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
Addiction
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Secondhand Smoke
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.
Effective Regulation
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.